Clinical trials
Non-alcoholic Fatty Liver clinical trials
Below are recruiting non-alcoholic fatty liver clinical trials, each written for real people, not researchers. We’re tracking 105 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06354088RecruitingPhase 1
Study of alpelisib for insulin resistance
This study tests a single dose of a drug called alpelisib (a PI3K inhibitor) to see how it affects insulin and blood sugar in people who are either insulin sensitive or insulin resistant. The goal is to understand why some people become resistant to insulin, which may help find new treatments for diabetes and related conditions.
New York, New YorkAges 18–70 - NCT05305287RecruitingPhase 4
Measuring liver energy use in people with diabetes and fatty liver disease
This study looks at how the liver uses energy (mitochondria) in people with type 2 diabetes and fatty liver disease. By understanding this, researchers may find better ways to treat liver problems.
San Antonio, TexasAges 18–80 - NCT05463796Recruiting
Prevention and early detection for people at high cancer risk
This study looks at surveillance (watching closely), prevention, and early “interception” steps to lower the chance that cancer will develop or be found later. It is for people with genetic risk, past cancer treatment exposures, strong family history, or certain early pre-cancer or high-risk conditions.
Boston, MassachusettsAges Any age - NCT03884075RecruitingPhase 2
Semaglutide study for fatty liver and how sugar affects the liver
This Phase 2 study tests how semaglutide (a diabetes medication also used for weight) affects fatty liver and the liver’s response to sugar. It may help people with non-alcoholic fatty liver disease understand whether the drug improves liver fat and related changes.
Bethesda, MarylandAges 18–100 - NCT05255978Recruiting
Follow-up study for hepatitis B with fatty liver
This observational study looks at people with chronic hepatitis B who also have fatty liver (non-alcoholic fatty liver disease). It follows how their liver health changes over time and may help doctors understand outcomes and risk factors.
Wuhan, HubeiAges 18 years+ - NCT06559878Enrolling by invitation
Liver Mitochondria Study in Fatty Liver Disease
This study looks at how the liver's mitochondria (the energy powerhouses of cells) work in people with fatty liver disease. Participants will have an MRI scan and receive a small amount of fat solution through an IV to see how the liver processes fat.
Helsinki, UusimaaAges 18–75 - NCT06493799RecruitingPhase 3
Injectable placenta extract for fatty liver disease
This trial tests an injectable medication made from human placenta to see if it can improve liver health in people with fatty liver disease (from alcohol or other causes). It may help lower liver enzyme levels and reduce liver damage.
Yongin-siAges 19–70 - NCT06626074Recruiting
MRI study for NASH diagnosis
This study looks at MRI scans to find better ways to diagnose NASH (a type of fatty liver disease with inflammation). If you are already scheduled for a liver biopsy for suspected NASH, an MRI might help researchers learn more about your condition.
Angers, FranceAges 18 years+ - NCT07452744Enrolling by invitation
Picroliv for non-alcoholic fatty liver disease
This study tests a plant-based medicine called Picroliv for people with non-alcoholic fatty liver disease (NAFLD). It aims to see if it is safe and can reduce fat in the liver.
Chandigarh, ChandigarhAges 18–60 - NCT07330830Recruiting
Genetics and fatty liver disease in Caribbean and Indian Ocean populations
This study looks at how a specific gene (PNPLA3) might affect non-alcoholic fatty liver disease (MASLD) in people from Guadeloupe, French Guiana, and Réunion Island. It aims to understand genetic differences that could explain why some people get the disease.
CayenneAges 18 years+ - NCT06374875RecruitingPhase 4
Does metabolic surgery reduce liver scarring?
This study tests if weight loss surgery can improve liver fibrosis (scarring) in people with obesity and advanced liver disease. It may help those considering surgery to know if their liver health can get better.
Phoenix, ArizonaAges 18–75 - NCT07221188RecruitingPhase 3
Efimosfermin alfa for liver scarring in MASH
This study tests an investigational drug called efimosfermin alfa to see if it is safe and tolerable for people who have liver scarring (F2 or F3 stage) from a condition called MASH. The goal is to find out if the drug can help without causing serious side effects.
Arcadia, CaliforniaAges 18–75 - NCT07221227RecruitingPhase 3
Testing a new drug for MASH with moderate scarring
This trial tests a new medicine called Efimosfermin Alfa for people with MASH (a fatty liver disease) and moderate liver scarring. It aims to see if the medicine can improve the liver condition.
Chandler, ArizonaAges 18–75 - NCT03025074Recruiting
Blood sample bank for liver disease research
This study collects blood samples to build a “biobank” (a stored library of samples) for researchers studying liver diseases like hepatitis, fatty liver disease, and liver cancer. It may help future testing and treatments by allowing scientists to study patterns in people with and without liver conditions.
Buffalo, New YorkAges 7 years+ - NCT03151473Recruiting
Study of adults with fatty liver and NASH over time
This is a long-term study that follows adults who are being managed for fatty liver (NAFL) or NASH to learn how these conditions change over time. It may help researchers better understand what to expect and how care decisions could be improved.
Hong KongAges 18 years+ - NCT03190538Recruiting
Study of fatty liver inflammation in Chinese children
This trial looks at nonalcoholic steatohepatitis (fatty liver with inflammation) in children. It is meant to test whether a new approach can help improve this liver problem without being caused by alcohol or other known liver diseases.
BeijingAges 1–18 - NCT03535142Recruiting
Fatty liver in people considering bariatric surgery
This study looks at how fatty liver disease may predict future liver health in people with severe weight gain. It compares people who are planning bariatric (weight-loss) surgery with similar people who are not, to better understand who may be at higher risk.
EsbjergAges 18 years+ - NCT03811236Recruiting
Test cold exposure to activate body fat and reduce liver fat
This study tests whether controlled cold exposure can activate “brown fat” and affect liver fat buildup. It may help people with excess liver fat, measured on imaging, but it has several health and medication exclusions.
ViennaAges 18–50 - NCT03875625Recruiting
Tracking body fat and liver fat after weight-loss treatment
This study looks at how body fat and liver fat change after bariatric (weight-loss) surgery or a lifestyle program. You may join if you have overweight or obesity and can safely have MRI scans, so researchers can compare results between treatment approaches.
Hong Kong, ShatinAges 18–65 - NCT04141592Recruiting
Study immune and disease changes in fatty liver
This study looks at what drives non-alcoholic fatty liver disease and how it affects the body, including immune-related changes. You may be invited if you have confirmed fatty liver disease or, alternatively, if you are a healthy person with no liver disease.
London, Greater LondonAges 18 years+ - NCT04190849Recruiting
Children’s liver fat disease registry in Europe
This is a registry study collecting information about children and teens with fatty liver disease that isn’t caused by alcohol. It aims to better understand this condition and may help future research and treatments.
MaastrichtAges Up to 18 years - NCT04340817Recruiting
Study of fatty liver in Nordic countries
This study looks at people with non-alcoholic fatty liver disease (fat buildup in the liver without heavy alcohol use). It may also include healthy volunteers for comparison, helping researchers understand the condition better.
Hvidovre, Capital Region DenmarkAges 18 years+ - NCT04365855Recruiting
Study of fatty liver risk in local adults
This study looks at how common fatty liver disease is and what factors may be linked to it in adults in Olmsted County. You may be asked about health history, alcohol use, and possibly to undergo MRI scans.
Rochester, MinnesotaAges 18 years+ - NCT04666402Recruiting
Testing better ways to diagnose early liver disease
This study looks at integrated diagnostic tests to find early liver problems sooner. It may help you (if referred to the community liver clinic) get more timely information about what’s going on.
Manchester, Greater ManchesterAges 18 years+
Hear when a new Non-alcoholic Fatty Liver trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for non-alcoholic fatty liver?
- Yes. Clin2 currently lists 105 recruiting non-alcoholic fatty liver studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a non-alcoholic fatty liver trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a non-alcoholic fatty liver trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.